6ztd Citations

Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.

Abstract

Chronic lymphocytic leukemia (CLL) major stereotyped subset 2 (IGHV3-21/IGLV3-21, ∼2.5% of all cases of CLL) is an aggressive disease variant, irrespective of the somatic hypermutation (SHM) status of the clonotypic IGHV gene. Minor stereotyped subset 169 (IGHV3-48/IGLV3-21, ∼0.2% of all cases of CLL) is related to subset 2, as it displays a highly similar variable antigen-binding site. We further explored this relationship through next-generation sequencing and crystallographic analysis of the clonotypic B-cell receptor immunoglobulin. Branching evolution of the predominant clonotype through intraclonal diversification in the context of ongoing SHM was evident in both heavy and light chain genes of both subsets. Molecular similarities between the 2 subsets were highlighted by the finding of shared SHMs within both the heavy and light chain genes in all analyzed cases at either the clonal or subclonal level. Particularly noteworthy in this respect was a ubiquitous SHM at the linker region between the variable and the constant domain of the IGLV3-21 light chains, previously reported as critical for immunoglobulin homotypic interactions underlying cell-autonomous signaling capacity. Notably, crystallographic analysis revealed that the IGLV3-21-bearing CLL subset 169 immunoglobulin retains the same geometry and contact residues for the homotypic intermolecular interaction observed in subset 2, including the SHM at the linker region, and, from a molecular standpoint, belong to a common structural mode of autologous recognition. Collectively, our findings document that stereotyped subsets 2 and 169 are very closely related, displaying shared immunoglobulin features that can be explained only in the context of shared functional selection.

Reviews citing this publication (6)

  1. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V, Kossida S, Belessi C, Rosenquist R, Ghia P, Langerak AW, Davi F, Stamatopoulos K, ERIC, the European Research Initiative on CLL. Leukemia 36 1961-1968 (2022)
  2. Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin. Gerousi M, Laidou S, Gemenetzi K, Stamatopoulos K, Chatzidimitriou A. Front Oncol 11 771454 (2021)
  3. Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia. Forconi F, Lanham SA, Chiodin G. Cancers (Basel) 14 663 (2022)
  4. Understanding Monoclonal B Cell Lymphocytosis: An Interplay of Genetic and Microenvironmental Factors. Galigalidou C, Zaragoza-Infante L, Iatrou A, Chatzidimitriou A, Stamatopoulos K, Agathangelidis A. Front Oncol 11 769612 (2021)
  5. Immunoglobulin Gene Sequence as an Inherited and Acquired Risk Factor for Chronic Lymphocytic Leukemia. Datta M, Jumaa H. Cancers (Basel) 14 3045 (2022)
  6. Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. Oder B, Chatzidimitriou A, Langerak AW, Rosenquist R, Österholm C. Front Oncol 13 1143811 (2023)

Articles citing this publication (6)

  1. Detection of early seeding of Richter transformation in chronic lymphocytic leukemia. Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, Dawson KJ, Kulis M, Diaz-Navarro A, Villamor N, Melero JL, Chapaprieta V, Dueso-Barroso A, Delgado J, Moia R, Ruiz-Gil S, Marchese D, Giró A, Verdaguer-Dot N, Romo M, Clot G, Rozman M, Frigola G, Rivas-Delgado A, Baumann T, Alcoceba M, González M, Climent F, Abrisqueta P, Castellví J, Bosch F, Aymerich M, Enjuanes A, Ruiz-Gaspà S, López-Guillermo A, Jares P, Beà S, Capella-Gutierrez S, Gelpí JL, López-Bigas N, Torrents D, Campbell PJ, Gut I, Rossi D, Gaidano G, Puente XS, Garcia-Roves PM, Colomer D, Heyn H, Maura F, Martín-Subero JI, Campo E. Nat Med 28 1662-1671 (2022)
  2. Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia. Kolijn PM, Muggen AF, Ljungström V, Agathangelidis A, Wolvers-Tettero ILM, Beverloo HB, Pál K, Hengeveld PJ, Darzentas N, Hendriks RW, van Dongen JJM, Rosenquist R, Langerak AW. Front Oncol 11 740083 (2021)
  3. IgIDivA: immunoglobulin intraclonal diversification analysis. Zaragoza-Infante L, Junet V, Pechlivanis N, Fragkouli SC, Amprachamian S, Koletsa T, Chatzidimitriou A, Papaioannou M, Stamatopoulos K, Agathangelidis A, Psomopoulos F. Brief Bioinform 23 bbac349 (2022)
  4. Letter Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21R110 chronic lymphocytic leukemia. Paschold L, Simnica D, Brito RB, Zhang T, Schultheiß C, Dierks C, Binder M. Blood Cancer J 12 49 (2022)
  5. Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity. Sofou E, Zaragoza-Infante L, Pechlivanis N, Karakatsoulis G, Notopoulou S, Stavroyianni N, Psomopoulos F, Georgiou E, de Septenville AL, Davi F, Agathangelidis A, Chatzidimitriou A, Stamatopoulos K. Front Oncol 12 1079772 (2022)
  6. The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia. Nicolò A, Linder AT, Jumaa H, Maity PC. Front Oncol 11 771669 (2021)


Related citations provided by authors (1)

  1. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia.. Minici C, Gounari M, Ubelhart R, Scarfo L, Duhren-von Minden M, Schneider D, Tasdogan A, Alkhatib A, Agathangelidis A, Ntoufa S, Chiorazzi N, Jumaa H, Stamatopoulos K, Ghia P, Degano M Nat Commun 8 15746- (2017)